- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 241/02 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
Patent holdings for IPC class C07D 241/02
Total number of patents in this class: 118
10-year publication summary
|
3
|
6
|
2
|
6
|
4
|
8
|
5
|
6
|
7
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| MannKind Corporation | 528 |
8 |
| Medibeacon, Inc. | 136 |
8 |
| Merck Sharp & Dohme LLC | 3748 |
7 |
| Betta Pharmaceuticals Co., Ltd. | 179 |
3 |
| Nippon Shinyaku Co., Ltd. | 325 |
3 |
| Novartis AG | 10849 |
2 |
| Bristol-myers Squibb Company | 4898 |
2 |
| Hoffmann-La Roche Inc. | 3418 |
2 |
| Merck Sharp & Dohme Corp. | 2194 |
2 |
| Janssen Pharmaceutica N.V. | 3392 |
2 |
| Pfizer Inc. | 3387 |
2 |
| Abbvie Inc. | 1800 |
2 |
| G1 Therapeutics, Inc. | 54 |
2 |
| Parion Sciences, Inc. | 61 |
2 |
| Toyama Chemical Co., Ltd. | 102 |
2 |
| Shanghai Forefront Pharma Co., Ltd. | 4 |
2 |
| Glaxo Group Limited | 4071 |
1 |
| F. Hoffmann-La Roche AG | 7925 |
1 |
| BASF SE | 20933 |
1 |
| Centre National de La Recherche Scientifique | 10418 |
1 |
| Other owners | 63 |